Patents by Inventor Navnath GAVANDE

Navnath GAVANDE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO
    Publication number: 20230293499
    Abstract: Described herein are compositions and methods for treating cancer in a subject. The compositions include selective NF-?B inhibitor inhibitors. The methods include inhibiting the binding of CARP-1 with NEMO.
    Type: Application
    Filed: January 27, 2023
    Publication date: September 21, 2023
    Inventors: ARUN K. RISHI, NAVNATH GAVANDE
  • REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS
    Publication number: 20230056729
    Abstract: This invention relates to RPA compounds or pharmaceutically acceptable salts thereof, and for the use of the compounds to treat cancer.
    Type: Application
    Filed: December 10, 2020
    Publication date: February 23, 2023
    Inventors: John J. TURCHI, Navnath GAVANDE
  • KU INHIBITORS AND THEIR USE
    Publication number: 20220089577
    Abstract: The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.
    Type: Application
    Filed: July 29, 2021
    Publication date: March 24, 2022
    Inventors: John J. TURCHI, Navnath GAVANDE, Pamela S. VANDERVERE-CAROZZA
  • XPA inhibitor compounds and their use
    Patent number: 11207296
    Abstract: The present disclosure relates to certain compounds having binding affinity for XPA, and uses thereof. Specifically, the present disclosure relates to the use of XPA inhibitors as described herein in in methods of treating cancer.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: December 28, 2021
    Assignee: Indiana University Research and Technology Corporation
    Inventors: John J. Turchi, Navnath Gavande, Pamela S. Vandervere-Carozza
  • Ku inhibitors and their use
    Patent number: 11098033
    Abstract: The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 24, 2021
    Assignee: Indiana University Research and Technology Corporation
    Inventors: John J Turchi, Navnath Gavande, Pamela S. Vandervere-Carozza
  • COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO
    Publication number: 20210106567
    Abstract: Described herein are compositions and methods for treating cancer in a subject. The compositions include selective NF-?B inhibitor inhibitors. The methods include inhibiting the binding of CARP-1 with NEMO.
    Type: Application
    Filed: October 1, 2020
    Publication date: April 15, 2021
    Inventors: ARUN K. RISHI, Navnath Gavande
  • KU INHIBITORS AND THEIR USE
    Publication number: 20200308154
    Abstract: The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.
    Type: Application
    Filed: May 24, 2017
    Publication date: October 1, 2020
    Inventors: John J TURCHI, Navnath GAVANDE, Pamela S. VANDERVERE-CAROZZA